Wolverine Trading
RGLS

Wolverine Trading’s Regulus Therapeutics RGLS Stock Holding History

Wolverine Trading’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-94
Closed -$25K – 4870
2016
Q4 		$25K Buy
+94
New +$30.6K ﹤0.01% 4294

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wolverine Trading's RGLS Position: Q1 2017 in Review

Wolverine Trading sold out of Regulus Therapeutics (RGLS) in Q1 2017, closing a stake of 94 shares — an estimated $25K sold.

Wolverine Trading first reported a position in RGLS in Q4 2016 and held it in 1 quarter. The position peaked at $25K in Q4 2016. 58 funds tracked by Wall St. Rank hold RGLS as of Q1 2017.

  • Wolverine Trading reported no remaining Regulus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Wolverine Trading sold 94 Regulus Therapeutics shares in Q1 2017, an estimated $25K.
  • Wolverine Trading first reported a position in Regulus Therapeutics in Q4 2016 and held it in 1 quarter.
  • Wolverine Trading's Regulus Therapeutics position peaked at $25K in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q1 2017.

Based on Wolverine Trading's 13F filing for Q1 2017, filed 15 May 2017.